Ginkgo Bioworks Holdings (DNA) Cash & Equivalents (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 8 years of Cash & Equivalents data on file, last reported at $143.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 53.95% year-over-year to $143.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143.9 million (down 53.95% YoY) and the FY2025 annual result came in at $167.2 million, down 70.23% from the prior year.
• Cash & Equivalents slipped to $143.9 million in Q1 2026, from $167.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.5 billion in Q1 2022 to a low of $111.1 million in Q3 2025.
• A 5-year average of $793.0 million and a median of $840.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 483.8% — and 2025, when it sank 81.98%.
• Tracing DNA's Cash & Equivalents over 5 years: stood at $1.3 billion in 2022, then dropped by 28.25% to $944.1 million in 2023, then tumbled by 40.52% to $561.6 million in 2024, then plunged by 70.23% to $167.2 million in 2025, then decreased by 13.96% to $143.9 million in 2026.
• The last three Cash & Equivalents figures came in at $143.9 million (Q1 2026), $167.2 million (Q4 2025), and $111.1 million (Q3 2025), per Business Quant data.